Last edition
News about Global Pharma
Lupin Launches Risperidone Extended-Release Injectable with 180-day CGT Exclusivity in the US
Risperidone Long-Acting Injectable is Lupin’s first product using its proprietary PrecisionSphere technology developed by its subsidiary Nanomi.
Global Pharma | 14/11/2025 | By Dineshwori
Uhlmann Pac-Systeme Opens New Branch in Jakarta to Establish Local Presence
Uhlmann Pac-Systeme, a global leader in pharmaceutical packaging systems, has further expanded its footprint in Southeast Asia with the opening of a new branch in Indonesia.
Global Pharma | 13/11/2025 | By Dineshwori
Sandoz and EirGenix Ink Global Licensing Deal for Pertuzumab Biosimilar
Sandoz, the global leader in affordable medicines, has signed a global license agreement with Taiwanese biotech company EirGenix to commercialise a proposed biosimilar of the oncology medicine pertuzumab. The milestone-based deal, valued at up to USD 152 million, includes an upfront payment and potential market-based incentives.
Global Pharma | 13/11/2025 | By Dineshwori
The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) and the Open Applications Group (OAGi) in the US have jointly unveiled a pioneering set of ontologies designed to enhance data interoperability and analytics capabilities across the biopharmaceutical industry.
Global Pharma | 13/11/2025 | By Dineshwori
GSK Pharma to Procure Solar Power from CleanMax for its Plant at Nashik, Maharashtra
GlaxoSmithKline Pharmaceuticals (GSK Pharma) has approved a plan to procure 4.95 MWp of solar power for its Nashik plant from Clean Max Enviro Energy Solutions to increase the company’s renewable energy intake and cut down greenhouse gas emissions.
Global Pharma | 11/11/2025 | By Mrinmoy Dey
Insilico Medicine and Eli Lilly Expand Collaboration to Accelerate AI-Driven Drug Discovery
The partnership aims to combine Insilico’s advanced Pharma.AI platforms with Lilly’s deep expertise in disease biology and drug development to jointly discover and advance innovative therapies for unmet medical needs.
Global Pharma | 11/11/2025 | By Dineshwori | 113
ABPI Calls for Urgent Steps to Boost UK Life Sciences Investment in Pre-Budget Submission
The Association of the British Pharmaceutical Industry (ABPI) has called on the government to take urgent action to reverse a decade-long decline in investment and restore the UK’s position as a global leader in life sciences.
Global Pharma | 10/11/2025 | By Dineshwori
Eli Lilly and SanegeneBio Partner to Develop RNAi Therapies for Metabolic Diseases
SanegeneBio, a clinical-stage biotechnology company developing RNAi therapeutics, has entered into a global research and licensing collaboration with Eli Lilly and Company to advance RNAi candidates for metabolic diseases.
Global Pharma | 10/11/2025 | By Dineshwori
FireGate Biotech Emerges as a New Force in Translational Immunology
Rather than chasing single indications, FireGate’s framework is designed as an adaptable immune network, a modular system capable of responding to multiple disease environments and evolving alongside the immune landscape itself.
Global Pharma | 07/11/2025 | By Dineshwori
Eli Lilly Appoints New Executives, Expands Senior Leadership Roles to Drive Next Phase of Growth
Eli Lilly has appointed Carole Ho and Adrienne Brown to lead the company’s expansion in neuroscience and immunology, while also broadening the responsibilities of Daniel Skovronsky and Jacob Van Naarden to further strengthen its leadership team.
Global Pharma | 07/11/2025 | By Dineshwori | 138
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy